Skip to content
Company Analysis

Abbott Laboratories ABT

A comprehensive view of key metrics, scores, and financial health for Abbott Laboratories

Overview of Abbott Laboratories

ABT NYQ
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Large Cap
Abbott Laboratories (ABT), is a Large Cap company, in the Medical Devices industry, last closed at $107.27, about 59.0% overvalued vs fair value, -16.6% 1Y return, placing in the top 10% of its sector.
Metrics P/E 33.6× Rev Growth 5.7% ROE 13.1% Gross Margin 56.4% Div Yield 1.89%
USD 107.27
2.66%
(Delayed)
• Vol 90d: 32.9%
52-Week Range
Market Cap
$164.43B
Enterprise Value
$191.67B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Good
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Good
Completeness: 82%
Confidence: 86%
Updated: Jul 5
Top Beats
No strong beats yet

Quick Facts

Website https://www.abbott.com
HQ Abbott Park, IL
Employees 115,000
Fiscal year Dec 31

Next Events

Earnings Jul 16 Estimated

Fair Value Snapshot

Bear Base Bull
$39
$44
$49
Current: $107.27 -59% vs base

Engine Room Money Flow™

Large Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$44.3B
5.7%%
Gross Profit
$25.0B
7.6%%
Operating Income (GAAP)
$8.1B
18%%
EBITDA
$12.1B
11.9%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
56.4%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$5.0B
67.7% of Free Cash Flow

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
1
Active Leaks
1/1
Improving
0
High Impact
0
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Abbott Laboratories's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
74
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
70
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing ABT's balance between Growth (20.8%), Profitability (42.1%), and Safety (37.1%). Growth 21% Safety 37% Profitability 42%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

39th percentile vs peers
39
Key Signals
Rev Growth YoY 5.7% 49p Revenue CAGR 3Y 0.5% 33p TSR 12.9% 63p EPS CAGR 3Y -1.7% 35p Asset Growth YoY 6.5% 63p
Strengths
  • FCF Margin in top 20% of peers (16.7%, 88th percentile)
  • Operating Margin in top 20% of peers (18.2%, 87th percentile)
  • ROIC in top 20% of peers (9.5%, 84th percentile)
  • Interest Coverage (EBITDA) in top 20% of peers (24.49, 89th percentile)
  • Cash Flow to Debt Ratio in top 20% of peers (1.17, 81th percentile)
Risks
  • EPS Growth YoY in bottom 20% of peers (-51.3%)
  • Growth below peer median (percentile: 39)

Profitability

79th percentile vs peers
80
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

70th percentile vs peers
70
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Abbott Laboratories.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$44.03
- - -
-59.0% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000